fbpx Skip to main content

Sickle cell disease (SCD) is a serious condition that disproportionately affects Black individuals, affecting 1 out of every 365 Black Americans. This hemoglobinopathy puts individuals at risk of developing pulmonary complications. Because of this fact, it is believed that SCD can increase the risk of COVID-19.

However, little research has been done to study the relationship between SCD and COVID-19. This study sought to investigate how COVID-19 affects people with SCD and address the disparities these individuals face in the context of socioeconomic status.

After analyzing data from a nationwide SCD registry, it was found that nearly 90% of patients with SCD who had confirmed cases of COVID-19 sought out emergency care, and 69% were hospitalized. These patients had a mean age of 28.6 years old. A total of 7% of them died. Of all the confirmed COVID-19 cases within the SCD registry, nearly 80% of these patients were Black.

Of note is the fact that COVID-19 deaths were not exclusive to severe cases of SCD or COVID-19. Of the reported deaths, 40% were among patients with milder SCD genotypes, and about 38% occurred among patients with mild or moderate COVID-19.

The implications of this study are twofold. First, SCD may increase the risk of COVID-19, including in younger patients. Second, it is important not to view the disparities faced by patients with SCD and COVID-19 in a vacuum. Patients with SCD often experience socioeconomic and healthcare access disparities, which can further worsen COVID-19 outcomes. It is critical, then, that patients with SCD are given prompt access to appropriate care, which could include providing transportation and subsidizing costs [1].

You May Also Like::  ACA's Reach Surges With 200,000 New Signups, More States Involved


[1] Panepinto, J. A., Brandow, A., Mucalo, L., Yusuf, F., Singh, A., Taylor, B., Woods, K., Payne, A. B., Peacock, G., & Schieve, L. A. (2020). Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20–May 21, 2020. Emerging Infectious Diseases, 26(10), 2473–2476. https://doi.org/10.3201/eid2610.202792

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More